Iroko to Present Phase 3 Data from Submicron NSAID Portfolio at American College of Rheumatology Annual Scientific Meeting

Submicron Diclofenac and Submicron Indomethacin Studies Selected for Three Poster Presentations

PHILADELPHIA, OCTOBER 14, 2013 — Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced today that data from Phase 3 studies of Iroko’s investigational non-steroidal anti-inflammatory drugs (NSAIDs) submicron diclofenac and submicron indomethacin will be presented in poster sessions at the upcoming 2013 American College of Rheumatology (ACR) Annual Scientific Meeting, taking place in San Diego, from October 25-30. Details of the poster sessions follow:

Tues., Oct. 29, 2013, 8:30 AM – 4:00 PM; Exhibit Hall B2-C-D

press_release_20131014

All data being presented at the meeting are under embargo until 4:30 PM Eastern Time on Saturday, October 26, 2013. For more information, please see the ACR website at:  http://acrannualmeeting.org.

About Low Dose Submicron NSAIDs

The risk of serious adverse events, including cardiovascular thrombotic events, myocardial infarction, stroke[1], gastrointestinal ulcers, gastrointestinal bleeds[2] and renal events such as acute renal failure[3] associated with NSAIDs is higher among patients receiving higher doses of NSAIDs[4]. Iroko is at the forefront of the development of submicron NSAIDs – new low dose drug products based on existing NSAIDs – using iCeutica Pty Ltd’s proprietary SoluMatrix™ technology exclusively licensed to Iroko for NSAIDs.  The SoluMatrix™ technology reduces standard oral NSAID drug particles to submicron particles that are approximately 10 times smaller than the original size. The reduction in particle size provides an increased surface area, resulting in faster dissolution.

About Iroko Pharmaceuticals, LLC

Iroko is a global specialty pharmaceutical company, based in Philadelphia, dedicated to advancing the science of analgesia. The company develops and globally commercializes pharmaceutical products. In addition to the Iroko products that are marketed worldwide, the company has a robust pipeline of submicron NSAID product candidates being developed using the proprietary SoluMatrix™ platform. For more information, visit www.iroko.com.

Media Contact: Jessica Donnelly for Iroko Pharmaceuticals, LLC, 212-798-9819

Investor Contact: Kate de Santis, Iroko Pharmaceuticals, LLC, 215-908-2264

[1] Howes LG. (2007 Oct.) Selective COX-2 inhibitors, NSAIDs and cardiovascular events – is celecoxib the safest choice? Ther Clin Risk Manag. 3(5): 831-845.

[2] Rahme E et. al. (2001 Aug). Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. Br J Clin Pharmacol. 52(2): 185-192.

[3] Annual Review of Medicine, Nonsteroidal Antiinflammatory Drugs and Renal Function. Vol. 35: 411-428. DOI: 10.1146/annurev.med.35.020184.002211.

[4] Risser A. (2009 Dec). NSAID Prescribing Precautions. Am Fam Physician. 80(12):1371-1378.